Nutriband Inc.

Equities

NTRB

US67092M2089

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 02:30:00 13/01/2026 am IST			5-day change	1st Jan Change
4.220 ^USD	-3.43%		-5.80%	-7.05%

29/12	EarthVision Bio Solutions Inc. signed an agreement to acquire 90% stake in Pocono Pharmaceuticals, Inc. from Nutriband Inc. for $5 million.	CI
18/12	Nutriband signs letter of intent with Qvanta Group of Companies	RE

Nutriband Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2025

Published on 12/11/2025 at 06:35 pm IST - Modified on 12/11/2025 at 04:31 pm IST

S&P Capital IQ

Nutriband Inc.

-3.43%

Nutriband Inc. reported earnings results for the third quarter and nine months ended October 31, 2025. For the third quarter, the company reported sales was USD 0.346058 million compared to USD 0.645796 million a year ago. Net loss was USD 3.87 million compared to USD 1.36 million a year ago. Basic loss per share from continuing operations was USD 0.32 compared to USD 0.12 a year ago.
For the nine months, sales was USD 1.64 million compared to USD 1.5 million a year ago. Net loss was USD 7.26 million compared to USD 4.97 million a year ago. Basic loss per share from continuing operations was USD 2.54 compared to USD 0.48 a year ago.

Latest news about Nutriband Inc.

29/12	EarthVision Bio Solutions Inc. signed an agreement to acquire 90% stake in Pocono Pharmaceuticals, Inc. from Nutriband Inc. for $5 million.	CI
18/12	Nutriband signs letter of intent with Qvanta Group of Companies	RE
11/12	Nutriband Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2025	CI
28/25/28	Nutriband Announces Successful Meeting Completed with United States Fda for Its Abuse Deterrent Fentanyl Patch	CI
27/25/27	Nutriband Announces CEO Changes	CI
10/25/10	Nutriband Inc. Signs Agreement with Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch	CI
08/25/08	Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology	CI
08/25/08	Nutriband Inc - files provisional patent application with USPTO for AVERSA technology	RE
10/25/10	Nutriband Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2025	CI
11/25/11	Nutriband CEO to Step Aside Temporarily to Seek Nomination in Irish Presidential Election	MT
11/25/11	Nutriband says Serguei Melnik will serve as interim CEO during election	RE
11/25/11	Nutriband Inc. Announces CEO Changes	CI
08/25/08	Sector Update: Health Care Stocks Gain Friday Afternoon	MT
08/25/08	Fda Grants Nutriband Meeting Request for Aversa?? Fentanyl Abuse Deterrent Fentanyl Patch	CI
08/25/08	Nutriband Says FDA Grants Meeting Request for Aversa Fentanyl Abuse-Deterrent Patch	MT
30/25/30	Nutriband Inc.(NasdaqCM:NTRB) added to Russell 3000E Index	CI
30/25/30	Nutriband Inc.(NasdaqCM:NTRB) added to Russell Microcap Index	CI
30/25/30	Nutriband Inc.(NasdaqCM:NTRB) added to Russell Microcap Growth Index	CI
30/25/30	Nutriband Inc.(NasdaqCM:NTRB) added to Russell 3000E Growth Index	CI
30/25/30	Nutriband Inc.(NasdaqCM:NTRB) added to Russell 3000E Growth Benchmark	CI
30/25/30	Nutriband Inc.(NasdaqCM:NTRB) added to Russell Microcap Growth Benchmark Index	CI
18/25/18	Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-Up for Aversa?? Fentanyl Abuse Deterrent Fentanyl Patch	CI
02/25/02	Nutriband Inc. Reports Revenue Results for the First Quarter Ended April 30, 2025	CI
02/25/02	Nutriband Inc. Provides Update on the Development of AVERSA Fentanyl	CI
31/25/31	Nutriband Inc. Reports Earnings Results for the First Quarter Ended April 30, 2025	CI

Chart Nutriband Inc.

Duration

Period

NTRB: Dynamic Chart

Company Profile

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company